# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aerie Pharmaceuticals (NASDAQ:AERI) reported quarterly losses of $(0.27) per share. This is a 62.5 percent increase over losses...
Upgrades
Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
According to data from Benzinga Pro, during Q2, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $33.31 million...
Truist Securities analyst Gregory Fraser downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Hold.
HC Wainwright & Co. analyst Oren Livnat downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.
Gainers